Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy.
Manabu MiyataSotaro OotoKenji YamashiroHiroshi TamuraMasayuki HataNaoko Ueda-ArakawaMunemitsu YoshikawaShogo NumaAkitaka TsujikawaPublished in: The British journal of ophthalmology (2018)
A PRN regimen for PCV may have a limited effect for the long-term maintenance of improved VA. Macular atrophy may occur more frequently with combination therapy and is possibly associated with the 5-year VA. Thus, combination therapy should be carefully selected for patients susceptible to macular atrophy.
Keyphrases
- combination therapy
- optical coherence tomography
- photodynamic therapy
- age related macular degeneration
- end stage renal disease
- diabetic retinopathy
- ejection fraction
- newly diagnosed
- vascular endothelial growth factor
- prognostic factors
- peritoneal dialysis
- stem cells
- cataract surgery
- patient reported outcomes
- fluorescence imaging
- smoking cessation
- patient reported